RxDoctor Payments Data

Jae Kim, MD

Neurology · Ocala, FLNPI 1841426400

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,169 of the $9,782 with a category attached, or 73.3%. 10 manufacturers reported payments, led by Microvention, Inc. at 44.7% of the total.

$9,782in general payments, 2019–2025

Across 131 payments — averaging $74.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Microvention, Inc.$4K
  • Johnson & Johnson$2K
  • Balt USA, LLC$1K
  • Penumbra, Inc.$724
  • Medtronic$544
  • Imperative Care, Inc$427
  • plus $613 from 4 others
$28,154in research payments, 2019–2025

Across 7 payments — averaging $4022.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$28K

What the payments were for

  • Travel & lodging$2,61327%
  • Food & beverage$7,16973%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,782 in reported general payments places this provider in the 70th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida →

Medicare billing

Part B allowed, 2024
$138,284
Medicare patients
170
Services billed
861

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClopidogrelClopidogrel Bisulfate14$158

Paid to pharmacies, not to this prescriber.

Other neurology in Ocala

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →